Humira adalimumab regulatory update

The European Commission approved an expanded label for Humira adalimumab from AbbVie to include treatment of chronic plaque psoriasis in children ages >=4 who have had an inadequate response to or for whom topical therapy and phototherapy are inappropriate. The human mAb against tumor necrosis factor (TNF) alpha is approved for the indication in adults. Humira is approved in the U.S. and EU for autoimmune indications, including active Crohn’s disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis, ulcerative colitis (UC) and polyarticular juvenile idiopathic arthritis. ...